Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 5/20 | 0.43 |
| ▸ | TSHR | P16473 | 4/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | CASP7 | P55210 | 1/20 | 0.41 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.39 |
| ▸ | UHRF1 | Q96T88 | 1/20 | 0.36 |
| ▸ | TERT | O14746 | 1/20 | 0.34 |
| ▸ | CASP1 | P29466 | 1/20 | 0.33 |
| ▸ | IDO1 | P14902 | 1/20 | 0.33 |
| ▸ | TDO2 | P48775 | 1/20 | 0.33 |
| ▸ | CD44 | P16070 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 3/20 | 0.32 |
| ▸ | HTT | P42858 | 2/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | HTR1D | P28221 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29548253 | 1.00 | CYP3A4 (0.43) | CYP3A4TSHRMAPK1ALDH1A1CYP1A2 | |
| SCHEMBL3678341 | 0.86 | CYP3A4 (0.43) | CYP3A4TSHRMAPK1ALDH1A1CYP1A2 | |
| SCHEMBL1755248 | 0.80 | NQO2 (0.38) | CYP3A4TSHRMAPK1ALDH1A1CYP1A2 | |
| SCHEMBL28012835 | 0.79 | CYP3A4 (0.38) | CYP3A4TSHRMAPK1ALDH1A1CYP1A2 | |
| SCHEMBL159075 | 0.79 | ALDH1A1 (0.43) | CYP3A4TSHRMAPK1ALDH1A1CYP1A2 | |
| SCHEMBL16728590 | 0.77 | ALDH1A1 (0.44) | CYP3A4TSHRMAPK1ALDH1A1CYP1A2 | |
| SCHEMBL1285327 | 0.77 | CYP3A4 (0.37) | CYP3A4TSHRMAPK1ALDH1A1CYP1A2 | |
| SCHEMBL560909 | 0.75 | CYP3A4 (0.35) | CYP3A4TSHRMAPK1ALDH1A1CYP1A2 | |
| SCHEMBL1733872 | 0.75 | KDM4E (0.60) | CYP3A4TSHRMAPK1ALDH1A1CYP1A2 | |
| SCHEMBL16550078 | 0.75 | CYP3A4 (0.40) | CYP3A4TSHRMAPK1ALDH1A1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4676922-A1 | BIFUNCTIONAL COMPOUNDS CAPABLE OF DEGRADING ANDROGEN RECEPTORS | Astrazeneca AB (SE) | 2026-01-14 | — | — | EP | disclosed |
| US-20250236610-A1 | 3-[(1H-PYRAZOL-4-YL)OXY]PYRAZIN-2-AMINE COMPOUNDS AS HPK1 INHIBITOR AND USE THEREOF | BEIGENE, LTD. (KY) | 2025-07-24 | — | — | US | disclosed |
| US-12195449-B2 | 3-[(1H-pyrazol-r-yl)oxy]pyrazin-2-amine compounds as HPK1 inhibitor and use thereof | BEIGENE, LTD. (KY) | 2025-01-14 | — | — | US | disclosed |
| US-20240317714-A1 | 3-[(1H-PYRAZOL-R-YL)OXY]PYRAZIN-2-AMINE COMPOUNDS AS HPK1 INHIBITOR AND USE THEREOF | BEIGENE, LTD. (KY) | 2024-09-26 | — | — | US | disclosed |
| WO-2024189488-A1 | BIFUNCTIONAL COMPOUNDS CAPABLE OF DEGRADING ANDROGEN RECEPTORS | ASTRAZENECA AB (SE) | 2024-09-19 | — | — | WO | disclosed |
| US-20240226115-A1 | AXL INHIBITOR COMPOUNDS | ARCUS BIOSCIENCES, INC. | 2024-07-11 | — | — | US | disclosed |
| US-20240226115-A1 | AXL INHIBITOR COMPOUNDS | ARCUS BIOSCIENCES, INC. | 2024-07-11 | — | — | US | disclosed |
| CN-117624130-A | 3- [ (1H-pyrazol-4-yl) oxy ] pyrazin-2-amine compounds as HPK1 inhibitors and uses thereof | 百济神州有限公司 | 2024-03-01 | — | — | CN | disclosed |
| CN-117624131-A | 3- [ (1H-pyrazol-4-yl) oxy ] pyrazin-2-amine compounds as HPK1 inhibitors and uses thereof | 百济神州有限公司 | 2024-03-01 | — | — | CN | disclosed |
| US-11857519-B2 | Compounds and methods for the targeted degradation of enhancer of zeste homolog 2 polypeptide | ARVINAS OPERATIONS, INC. (US) | 2024-01-02 | — | — | US | disclosed |
| EP-3165520-A1 | SUBSTITUTED BENZENE COMPOUNDS | Epizyme Inc (US) | 2017-05-10 | — | — | EP | disclosed |
| EP-3150580-A1 | ARYL- OR HETEROARYL-SUBSTITUTED BENZENE COMPOUNDS | Epizyme, Inc. (US) | 2017-04-05 | — | — | EP | disclosed |
| US-20170008904-A1 | MDM2-BASED MODULATORS OF PROTEOLYSIS AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS, INC. | 2017-01-12 | — | — | US | disclosed |
| EP-1227096-B1 | 4-OXOQUINOLIZINE ANTIMICROBIALS HAVING 2-PYRIDONE SKELETONS AS THE PARTIAL STRUCTURE | SATO PHARMA (JP) | 2004-09-22 | — | — | EP | disclosed |
| US-6525066-B2 | Bactericides; side effect reduction | SATO PHARMACEUTICAL CO., LTD. (JP) | 2003-02-25 | — | — | US | disclosed |
| EP-0882725-B1 | QUINOLONECARBOXYLIC ACID DERIVATIVES OR SALTS THEREOF | TOYAMA CHEMICAL CO LTD (JP) | 2002-12-18 | — | — | EP | disclosed |
| US-20020173517-A1 | 4-Oxoquinolizine antimicrobial having 2-pyridone skeleton as partial structure | SATO PHARMACEUTICAL CO., LTD. (JP) | 2002-11-21 | — | — | US | disclosed |
| EP-1227096-A1 | 4-OXOQUINOLIZINE ANTIMICROBIALS HAVING 2-PYRIDONE SKELETONS AS THE PARTIAL STRUCTURE | Sato Pharmaceutical Co. Ltd. (JP) | 2002-07-31 | — | — | EP | disclosed |
| US-6025370-A | METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS | TOYAMA CHEMICAL CO., LTD. (JP) | 2000-02-15 | — | — | US | disclosed |
| EP-0882725-A1 | QUINOLONECARBOXYLIC ACID DERIVATIVES OR SALTS THEREOF | TOYAMA CHEMICAL CO., LTD. (JP) | 1998-12-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240317714-A1 | 3-[(1H-PYRAZOL-R-YL)OXY]PYRAZIN-2-AMINE COMPOUNDS AS HPK1 INHIBITOR AND USE THEREOF | HIPK1, HIPK3, HIPK2 | CYP3A4 4304/4885TSHR 4200/4885MAPK1 378/4885 |
| US-20170008904-A1 | MDM2-BASED MODULATORS OF PROTEOLYSIS AND ASSOCIATED METHODS OF USE | MDM2, XIAP, TP53 | CYP3A4 3815/4885TSHR 3724/4885MAPK1 3133/4885 |
| US-20020173517-A1 | 4-Oxoquinolizine antimicrobial having 2-pyridone skeleton as partial structure | IL4I1, TLR5, IFNG | CYP3A4 64/4885TSHR 1867/4885MAPK1 220/4885 |
| US-11857519-B2 | Compounds and methods for the targeted degradation of enhancer of zeste homolog 2 polypeptide | CRBN, MDM2, VHL | CYP3A4 4840/4885TSHR 3794/4885MAPK1 4161/4885 |
| US-20240226115-A1 | AXL INHIBITOR COMPOUNDS | AXL, BTK, MERTK | CYP3A4 4316/4885TSHR 491/4885MAPK1 62/4885 |
| US-12195449-B2 | 3-[(1H-pyrazol-r-yl)oxy]pyrazin-2-amine compounds as HPK1 inhibitor and use thereof | HIPK1, HIPK3, HIPK2 | CYP3A4 4304/4885TSHR 4200/4885MAPK1 378/4885 |
| US-20250236610-A1 | 3-[(1H-PYRAZOL-4-YL)OXY]PYRAZIN-2-AMINE COMPOUNDS AS HPK1 INHIBITOR AND USE THEREOF | HIPK1, HIPK3, HIPK2 | CYP3A4 4192/4885TSHR 4360/4885MAPK1 366/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.